Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

566

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/26/29	HK$23.48	+6.05%	85,200
26/26/26	HK$22.14	-3.66%	85,500
25/26/25	HK$22.98	-2.96%	1,01,600
24/26/24	HK$23.68	+0.59%	1,20,800
23/26/23	HK$23.54	+2.71%	1,00,700

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

20.35CNY

Average target price

25.19CNY

Spread / Average Target

+23.78%

Consensus

Net sales - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. Other stock markets 01:38:52 29/06/2026 pm IST			5-day change	1st Jan Change
23.48 ^HKD	+6.05%		+4.26%	-22.97%

18/06	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
31/03	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	288.58Cr 332.95Cr 42Cr 37Cr 34Cr 32Cr 60Cr 4.01TCr 62Cr 412.94Cr 159.41Cr 1.98TCr 159.42Cr 155.92Cr 6.87TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	198.77Cr 229.33Cr 29Cr 26Cr 24Cr 22Cr 42Cr 2.76TCr 42Cr 284.42Cr 109.8Cr 1.36TCr 109.81Cr 107.4Cr 4.73TCr	EV / Sales 2026 *	2.91x	EV / Sales 2027 *	2.06x
Free-Float	23.17%	Yield 2026 *	-	Yield 2027 *	-

18/06	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
31/03	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/03	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
26/02	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
26/02	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI
06/02	Medtide Gets CSRC Nod for Hong Kong Share Full Circulation	MT
30/12	2,565,000 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025.	CI
26/25/26	Medtide Inc. Announces Change of Joint Company Secretary	CI
30/25/30	Hong Kong Stocks Drop as China Factory Struggles Persist; Unisound, IFBH, Medtide Shine on Debut	MT
30/25/30	Medtide Slips 1% in Quiet Hong Kong Debut	MT
30/25/30	Medtide Nets HK$429 Million from Hong Kong IPO, Prices Shares at Upper Limit of Guidance	MT
28/25/28	Medtide Inc. has completed an IPO in the amount of HKD 514.08 million.	CI
20/25/20	Medtide Inc. has filed an IPO in the amount of HKD 514.08 million.	CI

1 day	+6.05%
1 week	+4.26%
Current month	+8.00%
1 month	+6.24%
3 months	+4.63%
6 months	-22.41%
Current year	-22.97%

Medtide Inc. Share Price

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news : Medtide Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Net sales - Rate of surprise

1 week	22	24.2
1 month	19	24.5
Current year	19	30.46
1 year	19	41.72
3 years	19	41.72
5 years	19	41.72
10 years	19	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	11/06/2020
Wei Qun Xu DFI	Director of Finance/CFO	53	01/10/2020
Ling Mei Li IRC	Investor Relations Contact	50	01/09/2023

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	11/06/2020
Xiang Li Li BRD	Director/Board Member	51	27/01/2022
Xiang Li BRD	Director/Board Member	63	27/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/03	Xiang Li Li	Other	Director	6,82,01,112	48.0967%
09/03	Xiang Li Li	Other	Director	6,82,01,112	48.0967%
09/03	Qi Xu	Other	Chief Executive Officer	6,82,01,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+6.05%	+4.26%	-	-	40Cr
LONZA GROUP AG	+0.94%	+8.20%	-4.77%	+1.97%	4.62TCr
REVOLUTION MEDICINES, INC.	+5.79%	+16.17%	+423.57%	+634.63%	3.87TCr
IQVIA HOLDINGS INC.	+1.12%	+15.18%	+22.65%	-12.71%	3.19TCr
BEONE MEDICINES AG	+3.61%	+6.69%	+19.80%	+62.38%	3.11TCr
CELLTRION, INC.	+8.02%	+5.23%	+17.67%	+35.36%	2.38TCr
ASCENDIS PHARMA A/S	+1.13%	+15.66%	-	-	1.62TCr
MEDPACE HOLDINGS, INC.	+1.45%	+17.35%	+70.37%	+127.60%	1.51TCr
EUROFINS SCIENTIFIC SE	-1.13%	+9.05%	+12.03%	+18.95%	1.37TCr
IONIS PHARMACEUTICALS, INC.	-0.60%	+6.32%	+104.23%	+96.28%	1.34TCr
Average	+2.61%	+9.37%	+83.19%	+120.56%	2.31TCr
Weighted average by Cap.	+2.64%	+10.05%	+96.10%	+142.61%

	2026 *	2027 *
Net sales	68Cr 79Cr 10Cr 8.81Cr 8.13Cr 7.6Cr 14Cr 951.43Cr 15Cr 98Cr 38Cr 469.37Cr 38Cr 37Cr 1.63TCr	88Cr 101.03Cr 13Cr 11Cr 10Cr 9.72Cr 18Cr 1.22TCr 19Cr 125.3Cr 48Cr 600.8Cr 48Cr 47Cr 2.09TCr
Net income	-	-
Net Debt	-90Cr -103.62Cr -13Cr -12Cr -11Cr -9.97Cr -19Cr -1.25TCr -19Cr -128.51Cr -50Cr -616.21Cr -50Cr -49Cr -2.14TCr	-108.1Cr -124.72Cr -16Cr -14Cr -13Cr -12Cr -23Cr -1.5TCr -23Cr -154.68Cr -60Cr -741.7Cr -60Cr -58Cr -2.58TCr